These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38661237)

  • 1. Fostemsavir to overcome drug-drug interactions in heavily treatment-experienced people with HIV and cancer.
    Giacomelli A; Cattaneo D; Pozza G; Moschese D; Cossu MV; Dalu D; Gervasoni C
    J Antimicrob Chemother; 2024 Jul; 79(7):1708-1709. PubMed ID: 38661237
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.
    Muccini C; Canetti D; Castagna A; Spagnuolo V
    Drug Des Devel Ther; 2022; 16():297-304. PubMed ID: 35115764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating fostemsavir as a therapeutic option for patients with HIV.
    Berruti M; Pincino R; Taramasso L; Di Biagio A
    Expert Opin Pharmacother; 2021 Aug; 22(12):1539-1545. PubMed ID: 34125644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fostemsavir for the treatment of HIV.
    Seval N; Frank C; Kozal M
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):961-966. PubMed ID: 33331202
    [No Abstract]   [Full Text] [Related]  

  • 7. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fostemsavir: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
    Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
    Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
    Llibre JM; Aberg JA; Walmsley S; Velez J; Zala C; Crabtree Ramírez B; Shepherd B; Shah R; Clark A; Tenorio AR; Pierce A; Du F; Li B; Wang M; Chabria S; Warwick-Sanders M
    Front Immunol; 2024; 15():1394644. PubMed ID: 38863717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
    Magee M; Slater J; Mannino F; Ackerman P; Llamoso C; Moore K
    J Clin Pharmacol; 2021 Jul; 61(7):939-953. PubMed ID: 33368327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir.
    Saladini F; Giannini A; Giammarino F; Boccuto A; Dragoni F; Vicenti I; Zazzi M
    J Antimicrob Chemother; 2021 Nov; 76(12):3310-3312. PubMed ID: 34402509
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Gartland M; Cahn P; DeJesus E; Diaz RS; Grossberg R; Kozal M; Kumar P; Molina JM; Mendo Urbina F; Wang M; Du F; Chabria S; Clark A; Garside L; Krystal M; Mannino F; Pierce A; Ackerman P; Lataillade M
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0175121. PubMed ID: 35502922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
    N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.
    Anderson SJ; van Doornewaard A; Turner M; Jacob I; Clark A; Browning D; Schroeder M
    Clin Ther; 2022 Jun; 44(6):886-900. PubMed ID: 35610081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
    Wire MB; Magee M; Ackerman P; Llamoso C; Moore K
    HIV Res Clin Pract; 2021 Dec; 23(1):1-8. PubMed ID: 35285786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
    Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A
    J Antimicrob Chemother; 2020 Sep; 75(9):2547-2553. PubMed ID: 32464638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.
    Lagishetty C; Moore K; Ackerman P; Llamoso C; Magee M
    Clin Transl Sci; 2020 Jul; 13(4):769-776. PubMed ID: 32027457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.